Eledon Pharmaceuticals Reports 12th Participant Enrolled In Phase 2 BESTOW Trial Evaluating Tegoprubart For Prevention Of Organ Rejection
Eledon Pharmaceuticals报告称,第12名参与者参加了评估Tegoprubart预防器官排斥反应的2期试验
Eledon Pharmaceuticals Reports 12th Participant Enrolled In Phase 2 BESTOW Trial Evaluating Tegoprubart For Prevention Of Organ Rejection
Eledon Pharmaceuticals报告称,第12名参与者参加了评估Tegoprubart预防器官排斥反应的2期试验
使用浏览器的分享功能,分享给你的好友吧